Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show
Reviewed 16 sourcesPublished by PepVault
Zenagamtide is amycretin's official name: Novo's one-molecule GLP-1 and amylin drug. The trial results, all 36 registry trials and when phase 3 data is due.

- Last reviewed
- Sources
- 16
- Questions
- 8
- Compounds
- 5
The short answer
Zenagamtide is amycretin's official name, recommended by the WHO in 2026 for Novo Nordisk's single molecule that switches on both the GLP-1 and the amylin receptors. It is not approved anywhere. In trials, weekly shots took off 22% to 24% of body weight over 36 weeks in obesity and up to 14.6% in type 2 diabetes. Phase 3 began in February 2026.
- Zenagamtide, amycretin and NNC0487-0111 are one drug: the WHO name, the development name and Novo's code.
- One chain carries a GLP-1 piece and an amylin piece, the two signals CagriSema gives as two drugs.
- Weekly shots: 24.3% weight loss at 36 weeks on 60 mg in a 125-person trial; up to 14.6% in type 2 diabetes.
- 19 phase 3 trials are listed, shot and tablet; the earliest primary completions fall in mid-2028.
Evidence: Early human evidence: two phase 1 trials, a 125-person phase 1b/2a trial and two 36-week phase 2 trials in type 2 diabetes, all randomized and all funded by Novo Nordisk. Nineteen phase 3 trials are under way and none has reported; zenagamtide is not approved anywhere.

Is zenagamtide the same drug as amycretin?
Yes. Zenagamtide is the international nonproprietary name (INN), the official generic name the World Health Organization gives a medicine, for the molecule Novo Nordisk developed as amycretin. The WHO proposed it in List 133 in 2025 and recommended it in List 95 in 202667. Novo's own reports switched to "zenagamtide (previously amycretin)" in February 202610, and the 2026 papers use the new name34.
Three names point to the same drug, and you will meet all three:
- Zenagamtide: the WHO name, used in Novo's reports, the 2026 papers and the newest trial records.
- Amycretin: the development name, used in the 2025 papers and most news before 2026.
- NNC0487-0111: Novo's code, used in most ClinicalTrials.gov records, including AMAZE 115.
It matters in the registry: "amycretin" finds one trial, "zenagamtide" 13 and the code 231415. The tables below combine all three.

How does zenagamtide work?
It is two hormone signals built into one chain. The WHO's description reads like a parts list: a modified piece of human GLP-1, a short linker, then an artificial 33-amino-acid piece that switches on the amylin receptor, with a fatty side chain attached6. GLP-1 is the gut hormone behind semaglutide and tirzepatide: it curbs appetite and slows the stomach. Amylin is the fullness hormone the pancreas releases with insulin after a meal. The molecule also switches on the calcitonin receptor, a close relative of the amylin receptor3.
CagriSema sends the same two signals with two drugs in one shot, cagrilintide for amylin and semaglutide for GLP-1. Zenagamtide does it with one molecule, and that one molecule also works as a daily tablet.
The fatty side chain lets the drug ride on albumin, the main protein in blood, so it clears slowly: with normal kidney function, its half-life after one shot was 88.1 hours, about 3.7 days, which suits a weekly shot5.
Try it
How Amycretin builds up
An estimate from a half-life of about 3.7 days, one dose a week for four weeks. The shape of the level, not a measurement.
In obese rats, 21 days of the drug cut food intake by 47% and body weight by 18% compared with untreated rats, and in mice it reached the brain areas that control eating16. These are animal results; the human trials follow.
How much weight did people lose on zenagamtide shots?
The first weekly-shot trial took 125 adults with overweight or obesity at one clinic in San Antonio and stepped each group from 0.3 mg up to a different top dose1. The longer and higher the dose, the more weight came off, and the placebo groups barely moved1:
| Top weekly dose (trial) | Weeks | Zenagamtide | Placebo |
|---|---|---|---|
| 1.25 mg | 20 | −9.7% | +2.0% |
| 5 mg | 28 | −16.2% | +2.3% |
| 20 mg | 36 | −22.0% | +1.9% |
| 60 mg | 36 | −24.3% | −1.1% |
Two limits keep these numbers in proportion. The groups were small, and many people left the study early, a large share of them for reasons unrelated to side effects1. The 36-week figures are also early: the phase 3 weight trials measure their main result at 76 to 84 weeks1113.
PepVault charts your weigh-ins over time and logs each weekly shot beside them, so the curve you bring to your clinician is your own, not a trial average. Track your weight in PepVault
What did zenagamtide do in type 2 diabetes?
A 36-week phase 2 trial at 83 sites in 11 countries gave 262 adults on metformin (some also on an SGLT2 inhibitor) one of six weekly doses or placebo3. The main measure was HbA1c, a three-month average of blood sugar, which started at 7.8%3. Every dose lowered it more than placebo3. The weight numbers come from Novo's release at the ADA meeting in June 2026, counting people while they stayed on treatment9:
| Weekly dose (trial) | Weight change | HbA1c change (points) |
|---|---|---|
| 0.4 mg | −4.35% | −0.91 |
| 1.5 mg | −7.62% | −1.31 |
| 5 mg | −8.19% | −1.00 |
| 10 mg | −12.92% | −1.41 |
| 20 mg | −13.13% | −1.64 |
| 40 mg | −14.60% | −1.71 |
| Placebo | −2.10% | −0.14 |
Up to 89.1% of people reached an HbA1c under 7%8. The most interesting line in Novo's first release: people on the highest dose had been on it for only 4 weeks when the trial ended, and at the higher doses weight had not levelled off by week 368. Novo's November 2025 headline said up to 14.5%; its June release gives 14.5% as a dose-response model's estimate and 14.6% as the 40 mg group's result89.
Is there a zenagamtide pill?
Yes, the same molecule as a daily tablet, and it reached phase 3 in September 202613. The first human study of the drug was the tablet: 144 adults, single doses up to 25 mg, then a 12-week step-up to as much as 100 mg a day (two 50 mg tablets)2.
In the type 2 diabetes trial, 186 adults took 6, 25 or 50 mg a day for 36 weeks. HbA1c fell by 0.9, 1.3 and 1.4 points from about 8.0%, all more than placebo4, and weight fell by up to 10.1%, against 2.5% on placebo8. AMAZE 9 now tests five daily doses, from 6 mg to 100 mg, in about 950 people without diabetes for 76 weeks13. These are trial doses, and tablet milligrams do not translate to shot milligrams.
What side effects showed up in the zenagamtide trials?
The familiar GLP-1 pattern: stomach and gut effects lead, mostly mild to moderate. In the obesity shot trial they had mostly cleared by the study's end1. In the first tablet study, every event was mild or moderate, and gut effects made up 49% of them2.
In the diabetes tablet trial, gut effects rose with the dose: 26% of people on 6 mg, 41% on 25 mg and 47% on 50 mg, against 23% on placebo4. In the diabetes shot trial, 8% of people had a serious event, spread across every dose and placebo, and no one died3. Kidney function made little difference to blood levels: the authors judged that no dose change was needed for kidney impairment5.
Commonly reported: stomach and gut effects in every trial so far, most of them mild to moderate1234.
Which zenagamtide trials are running?
ClinicalTrials.gov lists 36 trials under the three names, every one sponsored by Novo Nordisk A/S (as of November 20, 2026)1415. Nineteen are phase 3: the AMAZE trials for weight, the AMBITION trials for type 2 diabetes, and two large heart trials. All are weekly shots except AMAZE 9, the tablet. Completion dates are the registry's estimates for the main result, not results dates.
| Phase 3 trial | NCT | What it tests | People | Primary completion (est.) | Status |
|---|---|---|---|---|---|
| AMAZE 1 | NCT07339423 | Obesity, vs placebo, 84 weeks | 1,150 | Jun 2029 | Recruiting |
| AMAZE 2 | NCT07533175 | Obesity with type 2 diabetes, vs placebo | 638 | Aug 2028 | Active, not recruiting |
| AMAZE 3 | NCT07571005 | Sleep apnea, no CPAP | 300 | Jul 2028 | Recruiting |
| AMAZE 4 | NCT07571109 | Sleep apnea on CPAP | 300 | Jun 2028 | Recruiting |
| AMAZE 5 | NCT07481630 | Knee osteoarthritis | 400 | Aug 2028 | Recruiting |
| AMAZE 6 | NCT07509307 | Knee osteoarthritis | 400 | Aug 2028 | Recruiting |
| AMAZE 7 | NCT07668414 | Obesity, vs semaglutide | 650 | Oct 2028 | Recruiting |
| AMAZE 8 | NCT07400107 | Obesity with type 2 diabetes, vs semaglutide | 985 | Dec 2028 | Active, not recruiting |
| AMAZE 9 | NCT07720271 | Daily tablet, vs placebo, 76 weeks | 950 | Jun 2028 | Recruiting |
| AMAZE 10 | NCT07822061 | Japan, vs placebo | 400 | Feb 2029 | Recruiting |
| AMAZE 12 | NCT07503210 | Keeping weight off, weeks 40 to 92 | 606 | Jun 2028 | Active, not recruiting |
| AMAZE 13 | NCT07668401 | Asia, vs placebo | 400 | Jan 2029 | Not yet recruiting |
| AMBITION 1 | NCT07931495 | Type 2 diabetes on diet and exercise | 200 | Jun 2028 | Not yet recruiting |
| AMBITION 2 | NCT07931547 | Type 2 diabetes with kidney disease, on basal insulin | 450 | Jul 2028 | Not yet recruiting |
| AMBITION 3 | NCT07931573 | Higher doses vs semaglutide | 1,200 | Jul 2028 | Not yet recruiting |
| AMBITION 4 | NCT07931599 | Lower doses vs semaglutide | 1,060 | Jul 2028 | Not yet recruiting |
| AMBITION 7 | NCT07797335 | High heart risk, vs insulin glargine | 1,778 | Jul 2028 | Recruiting |
| HF-POLARIS | NCT07567001 | Heart failure with obesity | 5,610 | Jul 2029 | Recruiting |
| AMBIENCE | NCT07861100 | Heart attack and stroke in heart disease | 8,500 | Sep 2030 | Not yet recruiting |
The other 17 are phase 1 and 2 studies of how the body handles the drug and practical questions, among them switching from semaglutide or tirzepatide1415.
| NCT | Phase | What it tests | People | Status (primary completion) |
|---|---|---|---|---|
| NCT05369390 | 1 | First in humans, tablet | 144 | Completed Jan 2024 |
| NCT06049329 | 1 | Tablet, Japanese men | 36 | Completed Dec 2023 |
| NCT06064006 | 2 (1b/2a) | Weekly shot, obesity | 125 | Completed Nov 2024 |
| NCT06461039 | 1 | Birth control pill, stomach emptying | 43 | Completed Mar 2025 |
| NCT06478563 | 1 | Tablet versions and food | 133 | Completed Jun 2025 |
| NCT06542874 | 2 | Type 2 diabetes, shot and tablet | 448 | Completed Oct 2025 |
| NCT06559527 | 1 | Reduced kidney function | 42 | Completed Feb 2025 |
| NCT06820476 | 1 | Tablet, Chinese adults | 29 | Completed May 2025 |
| NCT07121153 | 1 | Shot, Chinese adults | 36 | Completed Dec 2025 |
| NCT07508020 | 1 | Food intake and appetite | 120 | Recruiting, Jan 2028 |
| NCT07535307 | 1 | Insulin release in type 2 diabetes | 80 | Recruiting, Nov 2027 |
| NCT07587710 | 1 | Reduced liver function | 35 | Recruiting, Dec 2027 |
| NCT07757087 | 1 | Energy use after weight loss | 120 | Recruiting, Sep 2028 |
| NCT07815067 | 1 | Tablet: meal timing and water | 320 | Recruiting, Jun 2028 |
| NCT07855133 | 1 | Switching from semaglutide | 60 | Recruiting, Sep 2028 |
| NCT07868354 | 1 | Switching from tirzepatide | 60 | Recruiting, Sep 2028 |
| NCT07944118 | 1 | Fasting, paused doses and the stomach | 36 | Not yet recruiting, Jan 2028 |
When will zenagamtide phase 3 results come out?
Not before 2028, on Novo's timetable. As of November 20, 2026, no phase 3 trial has reported, and this page is updated when one does. The dates Novo has given, each its expectation rather than a fixed date1213:
- AMAZE 9 (tablet): results in the second half of 2028.
- AMAZE 7 (vs semaglutide): completion in the second half of 2028.
- AMBITION 7 (vs insulin glargine): completion in the second half of 2028.
- AMAZE 8 (vs semaglutide, with diabetes): results in the first half of 2029.
- AMAZE 10 (Japan): completion in the first half of 2029.
- HF-POLARIS (heart failure): results in the second half of 2029.
- AMBIENCE (heart attack and stroke): completion in the second half of 2030.
Novo's reports give no filing date. The registry's earliest primary completion dates fall in June 2028 (AMBITION 1, AMAZE 4, AMAZE 12 and AMAZE 9)1415, so a filing before late 2028 would be a surprise.
If you start a prescribed GLP-1 while these trials run, PepVault can remind you on your shot day and keep each dose and weigh-in in one log. Set reminders in PepVault
Sources
- Dahl K et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406:149-162. PubMed 40550231
- Gasiorek A et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial. Lancet. 2025;406:135-148. PubMed 40550229
- Mora P et al. Efficacy and safety of once-weekly subcutaneous zenagamtide in type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408:621-635. PubMed 42532080
- Mora P et al. Efficacy and safety of once-daily oral zenagamtide in adults with type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408:607-620. Erratum: Lancet. 2026;408:1704. PubMed 42532079
- Oldenburg LIK et al. Renal impairment does not affect pharmacokinetics, safety or tolerability of zenagamtide. Diabetes Obes Metab. 2026;28:8946-8954. PubMed 42443140
- World Health Organization. Proposed INN: List 133 (zenagamtide). WHO Drug Information. 2025;39(2). cdn.who.int
- World Health Organization. Recommended INN: List 95 (zenagamtide). WHO Drug Information. 2026;40(1). cdn.who.int
- Novo Nordisk A/S, Form 6-K: Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. November 25, 2025. sec.gov
- Novo Nordisk. Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes, presented at ADA 2026 (PR Newswire release). June 5, 2026. biospace.com
- Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026). February 3, 2026. sec.gov
- Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 31 March 2026 (company announcement No 30/2026). May 6, 2026. sec.gov
- Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 30 June 2026 (company announcement No 48/2026). August 4, 2026. sec.gov
- Novo Nordisk A/S, Form 6-K: Financial report for the period 1 January 2026 to 30 September 2026 (company announcement No 65/2026). November 4, 2026. sec.gov
- ClinicalTrials.gov. Studies listing zenagamtide (13 records; searched November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov. Studies listing NNC0487-0111 (23 records; searched November 20, 2026). clinicaltrials.gov
- Kuhre RE et al. The effect of amycretin, a unimolecular GLP-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025;118:105862. PubMed 40706446
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.